(Q40605148)

22 September 2017

title

Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma (English)

1 reference

22 September 2017

1 reference

4

Michael Weller

1 reference

22 September 2017

3

Jörg B Schulz

1 reference

22 September 2017

Ulrike Naumann

1

1 reference

22 September 2017

Robert Waltereit

series ordinal

2

1 reference

22 September 2017

publication date

1 January 2003

1 reference

Journal of Neuro-Oncology

22 September 2017

published in

1 reference

22 September 2017

volume

61

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

7-15

1 reference

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

22 September 2017

cites work

1 reference

12 December 2020

Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.

1 reference

12 December 2020

Niacinamide blocks 3-acetylpyridine toxicity of cerebellar granule cells in vitro

1 reference

12 December 2020

Adenovirus-mediated gene transfer of inhibitors of apoptosis protein delays apoptosis in cerebellar granule neurons.

1 reference

12 December 2020

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

12 December 2020

Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.

1 reference

12 December 2020

Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene

1 reference

12 December 2020

Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus

1 reference

12 December 2020

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

1 reference

12 December 2020

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

1 reference

12 December 2020

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

12 December 2020

Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis

1 reference

12 December 2020

CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release

1 reference

12 December 2020

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

12 December 2020

Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines

1 reference

12 December 2020

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

1 reference

12 December 2020

Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo

1 reference

12 December 2020

CD95 ligand: lethal weapon against malignant glioma?

1 reference

12 December 2020

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

12 December 2020

APO2 ligand: a novel lethal weapon against malignant glioma?

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1021248329980

1 reference

Dimensions Publication ID

22 September 2017

1034163757

0 references

1 reference